Page 3 - Indian Pharma

Fierce competition among new drug brands for share of India market

The competitive intensity is high between brands, at a time when volume growth in the domestic pharma market is on a slow lane

All provisions of medical devices rules to come into force from Oct 1: DCGI

Medical devices of all four categories (A, B, C, and D) will be brought under the regulation by October 1 and as of now only two groups (A and B) are being regulated, Drugs Controller General of India (DCGI) Rajeev Singh Raghuvanshi said on Wednesday. Speaking to reporters on the sidelines of the 9th International Pharmaceutical Exhibition (iPHEX) being organised by the Pharmaceuticals Exports Promotion Council (Pharmexcil) here, Raghuvanshi said the regulations would ensure quality in the production of medical devices. "In the medical devices, we are categorising into four groups. Two groups (A and B) are already notified. C and D are left which will happen from October 1," he said. The Union Cabinet on April 26 approved the National Medical Devices Policy, 2023 to give a thrust to the sector with quality controls. The market size of the medical devices sector in India is estimated to be USD 11 billion (approximately Rs 90,000 crore) in 2020 and its share in the global medical devi

Contaminated drugs: USFDA uncovers failures in India's pharma factories

The $50 billion sector is under the spotlight after a number of recent scandals linked to smaller, privately-held Indian companies, including the deaths of dozens of children in Gambia and Uzbekistan

Health min urges stakeholders to build trust in quality of Indian drugs

Union Health Minister Mansukh Mandaviya urged all the stakeholders on Sunday to steadfastly work towards building trust and confidence in the quality of Indian drugs, cosmetics and medical devices in domestic and export markets. It is of critical importance to ensure that the country's regulatory mechanisms are of impeccable standards that are sustained over time and space, Mandaviya said as he inaugurated a two-day "chintan shivir" on "Drugs: Quality Regulations and Enforcement" in Hyderabad. "How can we ensure that the confidence of the consumers of pharmaceuticals manufactured in India is upheld? I urge all the stakeholders to steadfastly work towards making the Indian drugs regulatory system among the best in the world, which could be emulated by other countries," he said. In his inaugural address, Mandaviya underlined the focus of the deliberative forum, saying, "The chintan shivir is a platform for all the stakeholders in the pharma and health sectors to deliberate on pathways

Lupin Pharma launches Lurasidone Hydrochloride Tablets in US

The generic equivalent of Latuda tablets has been launched in the US markets

Indian pharma R&D spends stay stagnant three years after pandemic downturn

Spends are now lower relative to sales than before Covid-19, stand at 4.4% of net sales, compared with 20% in the US

Cough syrup-linked deaths: Manufacturing activities stopped at Noida firm

All manufacturing activities at Marion Biotech's Noida unit have been stopped in view of reports of contamination of its cough syrup, Dok-1 Max, Union Health Minister Mansukh Mandaviya said on Friday. Further investigation in connection with the death of 18 children in Uzbekistan allegedly linked to the cough syrup is going on, the minister said in a tweet. "Following inspection by @CDSCO_INDIA_INF team in view of reports of contamination in cough syrup Dok1 Max, all manufacturing activities of Marion Biotech at NOIDA unit have been stopped yesterday night, while further investigation is ongoing," Mandaviya said. Government sources said Uzbek officials reached out to India on Thursday night regarding the cough syrup-linked deaths and seeking a thorough probe in the matter. A legal representative of the company had said on Thursday that the manufacturing of Dok-1 Max has stopped "for now". Marion Biotech does not sell Dok-1 Max in India and its only export has been to Uzbekistan, a

After Gambia, now Uzbekistan alleges Indian cold drug killed its children

Noida-based Marion Biotech's Dok-1 Max anti-cold medicine under scanner after the Central Asian nation blames it for 18 deaths

Zuventus first in world to launch aviptadil for ARDS commercially

Discovered in 1970, the drug was tested on severe Covid-19 patients on DCGI's direction

Who is responsible for the quality of Indian pharma exports?

WHO has issued a global alert over four cough syrups made by an Indian pharma company, for alleged death of 66 children in The Gambia. Who are responsible for quality checks of Indian pharma exports?

TMS Ep276: OPEC production cuts, Indian pharma exports, stocks, USB-C ports

How will OPEC production cuts affect India? Who is responsible for the quality of Indian pharma exports? Are consumption stocks a good bet now? What makes USB-C the best charging port? Answers here

Who is responsible for the quality of Indian pharma exports?

WHO has issued a global alert over four cough syrups made by an Indian pharma company, for alleged death of 66 children in The Gambia. Who are responsible for quality checks of Indian pharma exports?

Udaan to provide medicine delivery to pharmacies every 4-hour

As part of the new service offering, Udaan will provide medicine delivery to pharmacies every 4-hour with 4 delivery slot options in a day to order medicines across six cities

Indian pharma industry likely to grow to $130 bn by 2030, says IPA

The trade shows are jointly organised by Indian Pharma Machinery Manufacturers Association (IPMMA), Indian Analytical Instruments Association (IAIA) and Messe Muenchen

Inter-ministerial MoU inked for promotion of 'One Herb, One Standard'

A memorandum of understanding (MoU) was inked between the Pharmacopoeia Commission for Indian Medicine and Homoeopathy (Ministry of Ayush) and the Indian Pharmacopoeia Commission (Ministry of Health) here on Tuesday for inter-ministerial cooperation for the promotion and facilitation of "One Herb, One Standard". P K Prajapati, Director (in-charge) of the Pharmacopoeia Commission for Indian Medicine and Homoeopathy (PCIM&H), and Rajeev Singh Raghuvanshi, Secretary-cum-Scientific Director of the Indian Pharmacopoeia Commission (IPC), signed the MoU in the presence of Rajesh Kotecha, Secretary, Ministry of Ayush, according to a statement issued by the ministry. On the occasion, Kotecha said, "The primary objective of this MoU is the development of cooperative efforts between the PCIM&H and the IPC to promote public health by facilitating the development of harmonised herbal drug standards. Since both the PCIM&H and the IPC are working with the common cause, it is logical and .

Indian pharma industry may rebound to 8-11% growth rate, says Alkem

Alkem Laboratories expects the Indian pharmaceutical industry to rebound to 8-11 per cent growth rate with normalcy in activities as the pandemic eases out

Pharma SMEs stock up on a month's raw material amid supply disruptions

The lockdown in various Chinese provinces, including Shanghai, is likely to delay shipments by two weeks to a month, said domestic players.

Expand PLI scheme for pharma to make it research-linked, says industry

So far 55 drug manufacturers have been selected under the PLI scheme for pharma.

Govt removes export curbs on Remdesivir, active pharmaceutical ingredients

The Centre has also removed similar curbs for exports of organic LEDs (Light Emitting Diodes) and liquid crystals

US pricing pressure cloud over Indian pharma growth, say analysts

Complex pipeline, execution, and regulatory compliance hold key